{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ELTX","limit":50},"count":50,"signals":[{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect, or would not reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockhold","filed_date":"2026-03-16","accession":"0001601485-26-000032","full_text":"https://origin.rootz.global/static/filing/0001601485-26-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":29,"context":"cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability. We may use and integrate artificial intelligence into our business processes. Use of this rapidly evolving technology will require the application of significant resources to design, develop, test, and maintain such systems to help ensure that artificia","filed_date":"2026-03-12","accession":"0001601485-26-000027","full_text":"https://origin.rootz.global/static/filing/0001601485-26-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":124,"context":"licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in derivation proceedings in the USPTO","filed_date":"2026-03-12","accession":"0001601485-26-000027","full_text":"https://origin.rootz.global/static/filing/0001601485-26-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"eement and/or any of the other Documents. (s) Liens or liens means a lien, mortgage, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. (t) Material Adverse Effect means a material adverse effect on (a) the business, assets, property, prospects, operations or condition (financial or otherwise) of the Company and all of its Subsidiaries, taken as a whole, (b) th","filed_date":"2025-06-04","accession":"0001601485-25-000096","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"to be conducted at the Annual Meeting, and information about Elicio that you should consider when you vote your shares are described in this proxy statement.At the Annual Meeting, two people will be elected to our Board of Directors. In addition, we will ask stockholders to ratify the selection of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December31, 2025. The Board of D","filed_date":"2025-04-09","accession":"0001601485-25-000062","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"d tumors. We are currently evaluating ELI-002 in AMPLIFY-7P, a randomized Phase 2 trial to evaluate the efficacy and safety in patients with PDAC. In December 2024, we announced that we completed enrollment in our AMPLIFY-7P trial. We will continue to follow patients for up to 36 months. A disease-free survival event-driven interim analysis is expected in Q3 2025, depending on rate of event accrual.","filed_date":"2025-03-31","accession":"0001601485-25-000049","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":124,"context":"licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedi","filed_date":"2025-03-31","accession":"0001601485-25-000049","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"be conducted at the Annual Meeting, and information about Elicio that you should consider when you vote your shares are described in this proxy statement. At the Annual Meeting, three people will be elected to our Board of Directors. In addition, we will ask stockholders to (i) ratify the selection of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December&#xa0;31, 2024 and (","filed_date":"2024-09-27","accession":"0001140361-24-042209","full_text":"https://origin.rootz.global/static/filing/0001140361-24-042209.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"following compensation disclosure is intended to comply with the requirements applicable to smaller reporting companies. The following is a discussion and analysis of compensation arrangements of our named executive officers (Named Executive Officers). This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation pro","filed_date":"2024-04-29","accession":"0001140361-24-022682","full_text":"https://origin.rootz.global/static/filing/0001140361-24-022682.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"iation, and cell death (also referred to as apoptosis). Mutations to the KRAS gene result in expression of overactive KRAS protein, driving aberrant signaling and unregulated cell growth, which are hallmarks of cancer. Targeting mutated KRAS using immunotherapy presents several potential advantages. KRAS mutations are categorized as truncal mutations serving as a genetic driver of malignant changes w","filed_date":"2024-03-29","accession":"0001601485-24-000023","full_text":"https://origin.rootz.global/static/filing/0001601485-24-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":122,"context":"licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedi","filed_date":"2024-03-29","accession":"0001601485-24-000023","full_text":"https://origin.rootz.global/static/filing/0001601485-24-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"urt, body, agency or regulatory authority thereof, and any person exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to any of the foregoing. Material Adverse Effect means a circumstance that (i) could reasonably be expected to have a material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby or","filed_date":"2024-03-18","accession":"0001601485-24-000015","full_text":"https://origin.rootz.global/static/filing/0001601485-24-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"urt, body, agency or regulatory authority thereof, and any person exercising executive, legislative, judicial, regulatory, taxing or administrative functions of or pertaining to any of the foregoing. Material Adverse Effect means a circumstance that (i) could reasonably be expected to have a material adverse effect on the performance of this Agreement or the consummation of any  2 of the transactions contemplated hereby","filed_date":"2023-12-22","accession":"0001601485-23-000086","full_text":"https://origin.rootz.global/static/filing/0001601485-23-000086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"to obtain additional funding to develop its product candidates; |  | |  |  Elicios ability to conduct and complete nonclinical studies and clinical trials, |  | |  |  delays in the commencement, enrollment and timing of clinical trials; |  | |  |  the success of Elicios nonclinical studies and clinical trials through all phases of development; |  | |  |  any delays in regulatory review and approval","filed_date":"2023-06-02","accession":"0001140361-23-028077","full_text":"https://origin.rootz.global/static/filing/0001140361-23-028077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"e able to generate revenue from these product candidates in the foreseeable future, or at all. Any significant delays in obtaining approval for and commercializing its product candidates could have a material adverse impact on its business and financial condition.  The process of product candidate development and obtaining marketing approval is expensive, often takes many years and can vary substantially based upon the","filed_date":"2023-06-02","accession":"0001140361-23-028077","full_text":"https://origin.rootz.global/static/filing/0001140361-23-028077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"of our executive officers, we may be unable to continue our operations and meet our ongoing obligations if we do not successfully complete the Merger. Any of these unintended consequences may have a material adverse impact on our business, financial condition, and results of operations. We may not be able to comply with Nasdaqs continued listing standards. Our common stock trades on The Nasdaq Global Select Market (Nas","filed_date":"2023-03-17","accession":"0001601485-23-000011","full_text":"https://origin.rootz.global/static/filing/0001601485-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"ieves that Dr. Venkatesans leadership experience and investment experience in the biopharmaceutical industry qualify him to serve as a member of Angions Board. Jennifer J. Rhodes, J.D. Ms. Rhodes was appointed Executive Vice President and Chief Business Officer in March 2022 and she has served as, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020. From February 2019 to December 2022, Ms. Rhodes also served","filed_date":"2023-03-17","accession":"0001601485-23-000011","full_text":"https://origin.rootz.global/static/filing/0001601485-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"terms certain of our stockholders may not deem desirable. There is no guarantee we will be able to complete the 2022 Strategic Realignment process in a timely or successful manner, which could have a material adverse effect on our business. 40 Table of Contents Our recent organizational changes and cost cutting measures may not be successful. In July 2022, we implemented a reduction-in-force affecting a majority of our","filed_date":"2022-11-14","accession":"0001601485-22-000070","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000070.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"d research and development activities is subject to the political process, which is inherently fluid and unpredictable. The lack of appropriate funding or appropriate resource for the FDA, could have material adverse effect on our ability to develop ANG-3070 and our product candidates.  48 Table of Contents We have conducted and may continue to conduct future clinical trials outside of the United States. The FDA and oth","filed_date":"2022-05-16","accession":"0001601485-22-000037","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":38,"context":"ns Board of Directors is divided into three classes. Each class has a three-year term. Vacancies on the Board of Directors may be filled only by a majority of the directors then in office. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the directors successor is","filed_date":"2022-04-27","accession":"0001601485-22-000026","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"l receive or maintain regulatory approval and, without regulatory approval, we and our collaborators will not be able to market our product candidates. Delays or difficulties in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for ANG-3070 and our other product candidates. Clinical failure","filed_date":"2022-03-30","accession":"0001601485-22-000022","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"d research and development activities is subject to the political process, which is inherently fluid and unpredictable. The lack of appropriate funding or appropriate resource for the FDA, could have material adverse effect on our ability to develop ANG-3070 and our product candidates.  We have and may continue to conduct future clinical trials outside of the United States. The FDA and other regulatory authorities may n","filed_date":"2022-03-30","accession":"0001601485-22-000022","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"dosterone synthase) inhibitors, which we are investigating for the purpose of targeting aldosterone-related fibrotic diseases. In our lead ANG-3777 clinical development program, we have completed enrollment of all currently ongoing clinical trials. On October 26, 2021, we announced that the Phase 3 trial of ANG-3777 in DGF did not achieve its primary endpoint and the data were not expected to be suff","filed_date":"2021-11-12","accession":"0001601485-21-000068","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"t grants and contracts, or if we fail to remain eligible to receive grant funding, we may be required to significantly curtail one or more of our discovery or development programs, which could have a material adverse effect on our business, financial condition and results of operations. Risks Relating to the Development and Regulatory Approval of Our Product Candidates  COVID-19 could adversely impact our business, incl","filed_date":"2021-11-12","accession":"0001601485-21-000068","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000068.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"dosterone synthase) inhibitors, which we are investigating for the purpose of targeting aldosterone-related fibrotic diseases. In our lead ANG-3777 clinical development program, we have completed enrollment of the Phase 2 trial in cardiac surgery-associated acute kidney injury (CSA-AKI) and we have completed the Phase 2 trial in Brazil in patients with acute lung injury associated with COVID-19 pneum","filed_date":"2021-08-12","accession":"0001601485-21-000047","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"t grants and contracts, or if we fail to remain eligible to receive grant funding, we may be required to significantly curtail one or more of our discovery or development programs, which could have a material adverse effect on our business, financial condition and results of operations. Risks Relating to the Development and Regulatory Approval of Our Product Candidates  COVID-19 could adversely impact our business, incl","filed_date":"2021-08-12","accession":"0001601485-21-000047","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"reement with the Company, the Board or management of the Company. 28 Note 17Subsequent Events On April 29, 2021, the Company and Vifor Pharma issued a joint press release announcing completion of enrollment in AKI-002-15, the Phase 2 trial of ANG-3777 in acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. 29 Item 2. Management's Discussion and Analysis of Financial C","filed_date":"2021-05-17","accession":"0001601485-21-000017","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"t grants and contracts, or if we fail to remain eligible to receive grant funding, we may be required to significantly curtail one or more of our discovery or development programs, which could have a material adverse effect on our business, financial condition and results of operations. Risks Relating to the Development and Regulatory Approval of Our Product Candidates  COVID-19 could adversely impact our business, incl","filed_date":"2021-05-17","accession":"0001601485-21-000017","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":36,"context":"uding increased hospital days and re-admissions, as well as long-term costs, including costs associated with outpatient dialysis and other outpatient services. ANG-3777 for DGF. We have completed enrollment in a Phase 3 registration trial of ANG-3777 to improve kidney function and reduce the severity of DGF following deceased-donor kidney transplantation in patients showing evidence of early kidney d","filed_date":"2021-03-30","accession":"0001601485-21-000007","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"ruption, cyber-attack, security incident or any other catastrophic event, could disrupt our operations or the operations of third parties who provide vital support functions to us, which could have a material adverse effect on our business, results of operations, and financial condition. We are subject to numerous and varying data privacy and security laws, regulations and standards, and our failure to comply could resu","filed_date":"2021-03-30","accession":"0001601485-21-000007","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"and 2019 as the corresponding adjustment was made to the valuation allowance. Note 14Employee Benefit Plan Simple IRA plan The Company maintained a simple IRA plan (the Plan) for employees, including named executive officers, who satisfy certain eligibility requirements. The Company has elected to make matching contributions to the Plan of 100% of every dollar each participant defers into the plan up to a maximum deferr","filed_date":"2021-03-30","accession":"0001601485-21-000007","full_text":"https://origin.rootz.global/static/filing/0001601485-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":35,"context":"6401a_main_toc) ** days and re-admissions, as well as long-term costs, including costs associated with outpatient dialysis and other outpatient services.  ** ANG-3777 for DGF.** We have completed enrollment in a Phase 3 registration trial of ANG-3777 to improve kidney function and reduce the severity of DGF following deceased-donor kidney transplantation in patients showing evidence of early kidney d","filed_date":"2021-02-04","accession":"0001047469-21-000278","full_text":"https://origin.rootz.global/static/filing/0001047469-21-000278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"t grants and contracts, or if we fail to remain eligible to receive grant funding, we may be required to significantly curtail one or more of our discovery or development programs, which could have a material adverse effect on our business, financial condition and results of operations.  **Risks Relating to the Development and Regulatory Approval of Our Product Candidates** **COVID-19 could adversely impact our business","filed_date":"2021-02-04","accession":"0001047469-21-000278","full_text":"https://origin.rootz.global/static/filing/0001047469-21-000278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pro-rated for her partial service on the board.  191 [Table of Contents](#bg76401a_main_toc)  **EXECUTIVE COMPENSATION** The following is a discussion and analysis of compensation arrangements of our named executive officers (NEOs). This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compen","filed_date":"2021-02-04","accession":"0001047469-21-000278","full_text":"https://origin.rootz.global/static/filing/0001047469-21-000278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":35,"context":"6401a_main_toc) ** days and re-admissions, as well as long-term costs, including costs associated with outpatient dialysis and other outpatient services.  ** ANG-3777 for DGF.** We have completed enrollment in a Phase 3 registration trial of ANG-3777 to improve kidney function and reduce the severity of DGF following deceased-donor kidney transplantation in patients showing evidence of early kidney d","filed_date":"2021-01-15","accession":"0001047469-21-000107","full_text":"https://origin.rootz.global/static/filing/0001047469-21-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"t grants and contracts, or if we fail to remain eligible to receive grant funding, we may be required to significantly curtail one or more of our discovery or development programs, which could have a material adverse effect on our business, financial condition and results of operations.  **Risks Relating to the Development and Regulatory Approval of Our Product Candidates** **COVID-19 could adversely impact our business","filed_date":"2021-01-15","accession":"0001047469-21-000107","full_text":"https://origin.rootz.global/static/filing/0001047469-21-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"pro-rated for her partial service on the board.  190 [Table of Contents](#bg76401a_main_toc)  **EXECUTIVE COMPENSATION** The following is a discussion and analysis of compensation arrangements of our named executive officers (NEOs). This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compen","filed_date":"2021-01-15","accession":"0001047469-21-000107","full_text":"https://origin.rootz.global/static/filing/0001047469-21-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ated ELI-002 7P versus observation in patients with resected Stage I-III mKRAS-driven PDAC who had completed surgery and standard locoregional therapy and were radiographically free of disease at enrollment.The AMPLIFY-7P study did not meet its pre-specified primary DFS endpoint in the intent-to-treat population. However, DFS analyses showed an approximately 14% absolute DFS benefit during active tre","filed_date":"2026-08-13","accession":"0001601485-26-000056","full_text":"https://origin.rootz.global/static/filing/0001601485-26-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":93,"match_count":11,"context":"that Dr. Venkatesan's leadership experience and investment experience in the biopharmaceutical industry qualify him to serve as a member of our board of directors. John F. Neylan, M.D. Dr. Neylan was appointed Executive Vice President and Head of Research in March 2022, and he has served as our Chief Medical Officer since December 2018. From April 2015 to December 2018, Dr. Neylan served as Chief Medical Officer of Keryx, a biopha","filed_date":"2022-03-30","accession":"0001601485-22-000022","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"Our lead product candidate, ANG-3070, is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. Enrollment is ongoing in JUNIPER, a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (PPKD) and we expect to file an IND in idiopathic pulmonary fibrosis (IPF) by the end of 2022","filed_date":"2022-05-16","accession":"0001601485-22-000037","full_text":"https://origin.rootz.global/static/filing/0001601485-22-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":78,"match_count":6,"context":"not believe it is a party to any claim, proceeding or litigation, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. License Agreements 16 [Table of Contents](#i90e86c78fdd244088832607d0b0ad2ca_13) ELICIO THERAPEUTICS, INC.  Notes to Unaudited Interim Condensed Consolidated Financial Statements (Co","filed_date":"2025-05-13","accession":"0001601485-25-000074","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000074.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":65,"match_count":5,"context":"not believe it is a party to any claim, proceeding or litigation, the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. License Agreements In January 2016, Former Elicio entered into a license agreement to license certain intellectual property rights from the Massachusetts Institute of Technology (MIT","filed_date":"2026-08-13","accession":"0001601485-26-000056","full_text":"https://origin.rootz.global/static/filing/0001601485-26-000056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"election or nomination for election to the Board was approved by a vote of at least a majority (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director without objection to such nomination) of the directors then still in office who either were directors at the beginning of the 12-month period or whose election or nomination for election was previous","filed_date":"2024-02-02","accession":"0001601485-24-000013","full_text":"https://origin.rootz.global/static/filing/0001601485-24-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"he 2021 Incentive Award Plan (the \"2021 Plan\"). Mr.Connellys option vests over four years with 25% vesting on the firstanniversary of the grant date and the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to Mr.Connelly being employed or in continuous service to Elicio as defined in the 2021 Plan through such vesting date. In September 2024, Mr. Connell","filed_date":"2025-04-09","accession":"0001601485-25-000062","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":48,"match_count":6,"context":"tors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different. Restructuring and Long-Lived Asset Impairment Restructuring charges We recognize restructuring charges related to reorganization plans that have been committed by management. In connection with these activities, we record restructuring charges at fair value for one-t","filed_date":"2023-03-17","accession":"0001601485-23-000011","full_text":"https://origin.rootz.global/static/filing/0001601485-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"ence/company-branding/ZWxpY2lvLmNvbQ/images/2025-04-04_logo.png --- EX-99.1 2 d858884dex991.htm EX-99.1 **Exhibit 99.1** ***Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment** Phase 2 randomized study of ELI-002 enrolled 135 patients; formal interim analysis of disease-free survival (DFS) expected in H1 2025* **BOSTON** Dec. 3, 2024 Elicio Therapeutics, Inc. (Nasdaq:","filed_date":"2024-12-03","accession":"0001193125-24-269400","full_text":"https://origin.rootz.global/static/filing/0001193125-24-269400.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"lability of data from our clinical trials, including data anticipated from our Phase 1A trials of ELI - 002 2P and ELI - 002 7P and the Phase 2 trial of ELI - 002 7P; the timing for completion of enrollment in our Phase 2 trial of ELI - 002 7P; the timing of any planned investigational new drug application or new drug application; our plans to research, develop and commercialize our current and futur","filed_date":"2024-06-27","accession":"0001140361-24-031563","full_text":"https://origin.rootz.global/static/filing/0001140361-24-031563.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":39,"match_count":3,"context":"rtible preferred stock, convertible notes, promissory notes, the exercise of stock options and common warrants, the private placement of our securities, at-the-market offerings, and proceeds from the Merger with Angion Biomedica Corp. (Angion). Since inception, we have had significant annual operating losses. Our net loss was $39.6 million and $51.9 million for the years ended December31, 2025 and 2024, resp","filed_date":"2026-03-12","accession":"0001601485-26-000027","full_text":"https://origin.rootz.global/static/filing/0001601485-26-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"9/6/2023) Advanced: 68% had stage III or oligometastatic resected stage IV disease Pre-treated: All received prior chemo and surgery, 28% had prior radiation Baseline Characteristics Basket Trial EnrollmentMonotherapy (no chemo, CPI combo) Phase 1AELI-002 2PELI-002 2P Study Overview Phase 1 adjuvant dose-ranging study to assess safety and efficacy of ELI-002 2P in patients who completed standard ther","filed_date":"2025-01-23","accession":"0001601485-25-000009","full_text":"https://origin.rootz.global/static/filing/0001601485-25-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ELTX","company":"Elicio Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"9/6/2023) Advanced: 68% had stage III or oligometastatic resected stage IV disease Pre-treated: All received prior chemo and surgery, 28% had prior radiation Baseline Characteristics Basket Trial EnrollmentMonotherapy (no chemo, CPI combo) Phase 1AELI-002 2PAMPLIFY-201 Study Overview Phase 1 adjuvant dose-ranging study to assess safety and efficacy of ELI-002 2P in patients who completed standard the","filed_date":"2024-12-12","accession":"0001601485-24-000107","full_text":"https://origin.rootz.global/static/filing/0001601485-24-000107.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"aa86689e27cc3d275abb25f01871fe64d3075260a6c43a360d3e4f33ca2b8363","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"17720a3ca6c8f2020e8e017a83deffa972bd818a6dc74aaeea26fa79406427b4","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":464,"hourly_limit":500,"remaining":36,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}